NeoStem Awarded Grant To Develop New Treatment for Skin Wounds In Scleroderma PDF Print E-mail
Wednesday, 18 September 2013 13:40
NeoStem, as a leader in the emerging cellular therapy industry, announced that it had received an award under the Small Business Innovative Research Program of $147,765 for the “Development of Adult Pluripotent Very Small Embryonic Like (VSEL) Stem Cells to Treat Skin Wounds in Scleroderma” from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH-NIAMS). This award will fund studies to investigate the potential of very small embryonic-like stem cells (VSELs™) in treating difficult to heal wounds in an animal model of Scleroderma.

VSEL™ Technology offers the potential to go beyond the paracrine effect, yielding cells that actually differentiate into the target tissue and create true cellular regeneration.

The grant will support research to be headed by Denis O. Rodgerson, Ph.D., Director of Grants and Academic Liaison of NeoStem, and Dr. Vincent Falanga, M.D., The Barbara A. Gilchrest Professor of Dermatology and Professor of Biochemistry at the Boston University School of Medicine.

The study will employ the tight skin (Tsk) mouse to test the potential wound healing capabilities of autologous VSELs™ in treating difficult to heal skin ulcers in this disease. The Tsk mouse carries a heterogeneous mutation for the fibrillin-1 gene and rapidly exhibits the characteristic tight and thickened skin phenotype of Scleroderma patients. Depending on the results of the study, the Company may quality for up to an additional $1.5 million phase 2 grant for the indication from NIH-NIAMS.

“Our collaboration with Dr. Falanga, a recognized expert in the management of chronic wounds and fibrosis, offers NeoStem a solid foundation to advance its investigation into the use of  human VSELs™ in treating skin wounds and a host of other degenerative diseases and disorders in humans, including scleroderma,” said Dr. Denis O. Rodgerson.  “This study has the potential to advance  treatments that could one day help patients suffering from this and other debilitating autoimmune diseases.”

Source: NeoStem Press Release

 
More articles :

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» New, Non-invasive Test May Help Diagnose Pulmonary Hypertension in Scleroderma

In patients with Systemic Sclerosis (SSc) – or – a condition called pulmonary hypertension (PH) is a leading cause of death. Having PH means the blood pressure between the heart and lungs is elevated.The Need for New Tests for PH in SScThe...

» The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis

Theresa C. Barnes,Marina E. Anderson, and Robert J.MootsReceived 1 June 2011; Accepted 21 July 2011Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis, vasculopathy, and immunological abnormalities. Over recent years,...

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...

» We Need Your Help!

Today, the Scleroderma Care Foundation embarks upon a mission of vital importance, and we are counting on your help. One of our dearest patients and friend, , is on the verge of Renal or and we are seeking out a qualified kidney donor. Currently,...

» The registry of the German Network for Systemic Scleroderma

N. Hunzelmann, E. Genth, T. Krieg, W. Lehmacher, I. Melchers, M. Meurer, P. Moinzadeh, U. Mu¨ ller-Ladner, C. Pfeiffer, G. Riemekasten, E. Schulze-Lohoff, C. Sunderkoetter, M. Weber, M. Worm, P. Klaus, A. Rubbert, K. Steinbrink, B. Grundt, R. Hein,...